What is the share price of Advanced Enzyme Technologies Ltd (ADVENZYMES) today?
The share price of ADVENZYMES as on 27th July 2026 is ₹316.50. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Advanced Enzyme Technologies Ltd (ADVENZYMES) share?
The past returns of Advanced Enzyme Technologies Ltd (ADVENZYMES) share are- Past 1 week: -2.08%
- Past 1 month: -15.37%
- Past 3 months: 6.12%
- Past 6 months: 19.08%
- Past 1 year: -4.02%
- Past 3 years: 2.79%
- Past 5 years: -22.26%
What are the peers or stocks similar to Advanced Enzyme Technologies Ltd (ADVENZYMES)?
The peers or stocks similar to Advanced Enzyme Technologies Ltd (ADVENZYMES) include:What is the dividend yield % of Advanced Enzyme Technologies Ltd (ADVENZYMES) share?
The current dividend yield of Advanced Enzyme Technologies Ltd (ADVENZYMES) is 1.69.What is the market cap of Advanced Enzyme Technologies Ltd (ADVENZYMES) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Advanced Enzyme Technologies Ltd (ADVENZYMES) is ₹3553.56 Cr as of 27th July 2026.What is the 52 week high and low of Advanced Enzyme Technologies Ltd (ADVENZYMES) share?
The 52-week high of Advanced Enzyme Technologies Ltd (ADVENZYMES) is ₹419 and the 52-week low is ₹251.95.What is the PE and PB ratio of Advanced Enzyme Technologies Ltd (ADVENZYMES) stock?
The P/E (price-to-earnings) ratio of Advanced Enzyme Technologies Ltd (ADVENZYMES) is 21.06. The P/B (price-to-book) ratio is 2.11.Which sector does Advanced Enzyme Technologies Ltd (ADVENZYMES) belong to?
Advanced Enzyme Technologies Ltd (ADVENZYMES) belongs to the Materials sector & Specialty Chemicals sub-sector.How to buy Advanced Enzyme Technologies Ltd (ADVENZYMES) shares?
You can directly buy Advanced Enzyme Technologies Ltd (ADVENZYMES) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Advanced Enzyme Technologies Ltd
ADVENZYMES Share Price
NSE₹316.500.27% (-0.85)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
ADVENZYMES Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
ADVENZYMES Performance & Key Metrics
ADVENZYMES Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 21.06 | 2.11 | 1.69% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 23.95 | 3.15 | 1.41% |
100%
Analysts have suggested that investors can buy this stock
from 1 analyst
Price Upside
Earnings Growth
Rev. Growth
ADVENZYMES Company Profile
Advanced Enzyme Technologies is engaged in the research and development, manufacturing and marketing of over 400 products developed from over 60 indigenous enzymes.
FLUOROCHEM
PE Ratio
87.53
87.53
1Y Return
27.89%
27.89%
Buy Reco %
73.33
73.33
NAVINFLUOR
PE Ratio
58.14
58.14
1Y Return
48.10%
48.10%
Buy Reco %
77.78
77.78
AETHER
PE Ratio
86.33
86.33
1Y Return
76.67%
76.67%
Buy Reco %
60.00
60.00
AARTIIND
PE Ratio
41.36
41.36
1Y Return
10.17%
10.17%
Buy Reco %
83.33
83.33
FINEORG
PE Ratio
35.49
35.49
1Y Return
10.35%
10.35%
Buy Reco %
80.00
80.00
ADVENZYMES Sentiment Analysis
ADVENZYMES Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
ADVENZYMES Stock Summary · May 2026
The company reported a strong top‑line quarter driven by product-led growth but flagged near-term margin pressure from inflation and U.S. market headwinds. Q4 revenue from operations was INR 2,034 million and Q4 EBITDA INR 632 million, with management describing the quarter as record revenue for FY2026 and performance in line with prior guidance. Leadership emphasized a strategic reorientation toward R&D-backed, higher-value offerings—backed by ongoing filings, a new Nashik R&D center coming online later in the year, and planned incremental R&D spend and capex—while subsidiaries showed clear operational improvements contributing to consolidated margins. Growth was concentrated in Human Healthcare and a pronounced Serratiopeptidase-led uplift that management said has been largely volume-driven, though they will limit disclosure of metrics; at the same time the U.S. business contracted and tariff, fuel and input inflation are creating competitiveness and margin challenges. Management expects to pursue productivity and cost actions, intends gradual price pass-through, will defer major capacity decisions until after September, and sees FY27 margins broadly steady with possible 1–2% variability.
ADVENZYMES Stock Growth Drivers
ADVENZYMES Stock Growth Drivers
6Robust Financial Performance and Margin Expansion
The company delivered record FY2026 top-line and strong profitability expansion: Q4 revenue rose to INR
Operational Resilience and Scalable Capacity
The company maintained a highly consistent supply track record despite global supply-chain disruptions, demonstrating continuity
ADVENZYMES Stock Challenges
ADVENZYMES Stock Challenges
5Rising input, logistics and supply‑chain inflation driving near‑term margin pressure
Global supply‑chain disruptions, heightened trade restrictions and escalating input costs for energy, fuel, salt, solvents,
Persistent U.S. market weakness compounded by tariff and regulatory uncertainty
The U.S. business has underperformed materially, with an approximate 11% quarter‑on‑quarter revenue decline in INR
ADVENZYMES Forecast
ADVENZYMES Forecasts
Price
Revenue
Earnings
ADVENZYMES Share Price Forecast
ADVENZYMES Share Price Forecast
2026
Current
₹317.35
Baseline
Forecast for Jul 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹317.35
Baseline
Forecast for Jul 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
ADVENZYMES Company Revenue Forecast
ADVENZYMES Company Revenue Forecast
2026
Current
₹796.73
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
2026
Current
₹796.73
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
ADVENZYMES Stock EPS (Earnings Per Share) Forecast
ADVENZYMES Stock EPS (Earnings Per Share) Forecast
2026
Current
₹15.08
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹15.08
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
ADVENZYMES
ADVENZYMES
Income
Balance Sheet
Cash Flow
Quarterly Normal View
ADVENZYMES Income Statement
ADVENZYMES Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 175.33 | 167.31 | 161.52 | 155.71 | 176.80 | 175.92 | 194.76 | 194.81 | 191.66 | 210.71 | ||||||||||
Operating & Other expenses | 107.17 | 117.58 | 103.36 | 103.68 | 113.86 | 121.58 | 129.48 | 124.47 | 122.60 | 140.14 | ||||||||||
EBITDA | 68.16 | 49.73 | 58.16 | 52.03 | 62.94 | 54.34 | 65.28 | 70.34 | 69.06 | 70.57 | ||||||||||
| Depreciation/Amortization | 8.60 | 9.28 | 8.61 | 8.90 | 8.97 | 10.08 | 9.62 | 10.08 | 10.21 | 10.19 | ||||||||||
| PBIT | 59.56 | 40.45 | 49.55 | 43.13 | 53.97 | 44.26 | 55.66 | 60.26 | 58.85 | 60.38 | ||||||||||
| Interest & Other Items | 0.68 | 0.85 | 0.87 | 0.93 | 0.94 | 0.81 | 0.76 | 0.72 | 0.57 | 0.57 | ||||||||||
| PBT | 58.88 | 39.60 | 48.68 | 42.20 | 53.03 | 43.45 | 54.90 | 59.54 | 58.28 | 59.81 | ||||||||||
| Taxes & Other Items | 17.11 | 11.30 | 14.52 | 9.37 | 15.37 | 16.98 | 14.97 | 16.22 | 15.79 | 16.84 | ||||||||||
| Net Income | 41.77 | 28.30 | 34.16 | 32.83 | 37.66 | 26.47 | 39.93 | 43.32 | 42.49 | 42.97 | ||||||||||
| EPS | 3.74 | 2.53 | 3.05 | 2.94 | 3.36 | 2.37 | 3.57 | 3.87 | 3.80 | 3.84 |
ADVENZYMES Company Updates
ADVENZYMES Stock Peers
ADVENZYMES Past Performance & Peer Comparison
ADVENZYMES Past Performance & Peer Comparison
Comparing 3 stocks from
MaterialsSpecialty Chemicals
Compare valuation on Screener
MaterialsSpecialty Chemicals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Advanced Enzyme Technologies Ltd | 21.06 | 2.11 | 1.69% |
| Gujarat Fluorochemicals Ltd | 87.53 | 6.88 | 0.07% |
| Navin Fluorine International Ltd | 58.14 | 9.71 | 0.11% |
| Aether Industries Ltd | 86.33 | 8.51 | — |
ADVENZYMES Stock Price Comparison
Compare ADVENZYMES with any stock or ETFCompare ADVENZYMES with any stock or ETF
ADVENZYMES
ADVENZYMES Holdings
ADVENZYMES Shareholdings
ADVENZYMES Promoter Holdings Trend
ADVENZYMES Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ADVENZYMES Institutional Holdings Trend
ADVENZYMES Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Increased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has increased by 1.22%
ADVENZYMES Shareholding Pattern
ADVENZYMES Shareholding Pattern
ADVENZYMES Shareholding History
ADVENZYMES Shareholding History
Foreign Institutions
Mutual Funds Invested in ADVENZYMES
Mutual Funds Invested in ADVENZYMES
No mutual funds holding trends are available
Top 5 Mutual Funds holding Advanced Enzyme Technologies Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.8617% | Percentage of the fund’s portfolio invested in the stock 1.13% | Change in the portfolio weight of the stock over the last 3 months 0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 33/66 (+3) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.6965% | Percentage of the fund’s portfolio invested in the stock 1.84% | Change in the portfolio weight of the stock over the last 3 months 0.06% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 17/59 (+1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.1127% | Percentage of the fund’s portfolio invested in the stock 0.16% | Change in the portfolio weight of the stock over the last 3 months -0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 118/255 (-2) |
Compare 3-month MF holding change on Screener
smallcases containing ADVENZYMES stock
smallcases containing ADVENZYMES stock
Looks like this stock is not in any smallcase yet.
ADVENZYMES Events
ADVENZYMES Events
ADVENZYMES Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ADVENZYMES has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.69%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹16.85 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ADVENZYMES Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ADVENZYMES has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.69%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹16.85 every year
ADVENZYMES Upcoming Dividends
ADVENZYMES Upcoming Dividends
No upcoming dividends are available
ADVENZYMES Past Dividends
ADVENZYMES Past Dividends
Cash Dividend
Ex DateEx DateJul 23, 2025
Final
Final | Div/Share: ₹1.20
Dividend/Share
₹1.20
Ex DateEx Date
Jul 23, 2025
Cash Dividend
Ex DateEx DateMay 16, 2025
Interim
Interim | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
May 16, 2025
Cash Dividend
Ex DateEx DateJul 18, 2024
Final
Final | Div/Share: ₹1.10
Dividend/Share
₹1.10
Ex DateEx Date
Jul 18, 2024
Cash Dividend
Ex DateEx DateMay 17, 2024
Interim
Interim | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
May 17, 2024
Cash Dividend
Ex DateEx DateAug 4, 2023
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Aug 4, 2023
ADVENZYMES Stock News & Opinions
ADVENZYMES Stock News & Opinions
Articles & Videos
Corporate
Corporate
Advanced Enzyme Techs. to conduct AGMAdvanced Enzyme Techs. announced that the Annual General Meeting(AGM) of the company will be held on 31 July 2026.
3 weeks agoCapital Market - Live
Corporate
Corporate
Advanced Enzyme Technologies announces cessation of directorAdvanced Enzyme Technologies announced the cessation of Rajshree Patel (DIN - 08761022) on completion of her second term as Independent Director of the company on 11 June 2026.
1 month agoCapital Market - Live
Corporate
Corporate
Board of Advanced Enzyme Techs. recommends final dividendAdvanced Enzyme Techs. announced that the Board of Directors of the Company at its meeting held on 9 May 2026, inter alia, have recommended the final dividend of Rs 1.35 per equity Share (i.e. 67.5%) , subject to the approval of the shareholders.
2 months agoCapital Market - Live
Earnings
Earnings
Advanced Enzyme Technologies consolidated net profit rises 62.24% in the March 2026 quarterNet profit of Advanced Enzyme Technologies rose 62.24% to Rs 42.96 crore in the quarter ended March 2026 as against Rs 26.48 crore during the previous quarter ended March 2025. Sales rose 21.65% to Rs 203.37 crore in the quarter ended March 2026 as against Rs 167.18 crore during the previous quarter ended March 2025. For the full year,net profit rose 28.68% to Rs 168.72 crore in the year ended March 2026 as against Rs 131.12 crore during the previous year ended March 2025. Sales rose 17.09% to Rs 745.76 crore in the year ended March 2026 as against Rs 636.91 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales203.37167.18 22 745.76636.91 17 OPM %31.0927.28 -30.7230.53 - PBDT69.8953.54 31 261.27223.92 17 PBT59.6943.46 37 221.18187.36 18 NP42.9626.48 62 168.72131.12 29 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Corporate
Advanced Enzyme Technologies receives ratings action from ICRAAdvanced Enzyme Technologies announced that ICRA has rated the company's debt facilities of Rs 100 crore at ICRA AA-; Stable; ICRA A1+. Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Earnings
Advanced Enzyme Technologies consolidated net profit rises 12.88% in the December 2025 quarterNet profit of Advanced Enzyme Technologies rose 12.88% to Rs 42.50 crore in the quarter ended December 2025 as against Rs 37.65 crore during the previous quarter ended December 2024. Sales rose 1.68% to Rs 171.95 crore in the quarter ended December 2025 as against Rs 169.11 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales171.95169.11 2 OPM %28.7032.67 - PBDT57.2561.99 -8 PBT47.0453.02 -11 NP42.5037.65 13 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Corporate
Advanced Enzyme Techs. to hold board meetingAdvanced Enzyme Techs. will hold a meeting of the Board of Directors of the Company on 31 January 2026.Powered by Capital Market - Live
6 months agoCapital Market - Live
Spotlight
Spotlight
Advanced Enzyme surges after strong Q2 performanceTotal expenditure for the period under review added up to Rs 135.27 crore, up 19.2% YoY. This was primarily due to higher raw material costs (up 24.8% YoY), higher employee expenses (up 10.8% YoY) and higher other expenses (up 14.3% YoY). Profit before tax in Q2 FY26 stood at Rs 59.54 crore, up by 41% from Rs 42.21 crore recorded in Q2 FY25. Advanced Enzyme Technologies is a research driven company with global leadership in the manufacturing of enzymes and probiotics. The company provides eco-safe solutions to a wide variety of industries like human health care and nutrition, animal nutrition, baking, fruit & vegetable processing, brewing & malting, grain processing, protein modification, dairy processing, specialty applications, textile processing and others. Its aim is to replace traditionally used chemicals with eco-friendly enzymatic solutions. Powered by Capital Market - Live
8 months agoCapital Market - Live
Earnings
Earnings
Advanced Enzyme Technologies consolidated net profit rises 31.98% in the September 2025 quarterNet profit of Advanced Enzyme Technologies rose 31.98% to Rs 43.33 crore in the quarter ended September 2025 as against Rs 32.83 crore during the previous quarter ended September 2024. Sales rose 26.30% to Rs 184.53 crore in the quarter ended September 2025 as against Rs 146.10 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales184.53146.10 26 OPM %32.5529.03 - PBDT69.6251.10 36 PBT59.5442.21 41 NP43.3332.83 32 Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Corporate
Advanced Enzyme Techs. to hold board meetingAdvanced Enzyme Techs. will hold a meeting of the Board of Directors of the Company on 12 November 2025.Powered by Capital Market - Live
8 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 9.3%, vs industry avg of 13.78%
Over the last 5 years, market share decreased from 0.84% to 0.64%
Over the last 5 years, net income has grown at a yearly rate of 2.91%, vs industry avg of 19.4%